Menu
  • Join
  • Login
  • Contact
 

Search abstracts


The New Drug Development for Ischemic Stroke in China

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: WANG, Xiaoliang (Institute of Materia Medica, CAMS, Pharmacology, Beijing, China)
  • Co-author(s): Xiaoliang Wang: Pharmacology, Institute of Materia Medica, CAMS, Beijing, China
    Ling wang: Pharmacology, Institute of Materia Medica, CAMS, Beijing, China;Pharmacology, Institute of Materia Medica, CAMS, Beijing, China
    Shaofeng Xu: Pharmacology, Institute of Materia Medica, CAMS, Beijing, China
    Nan Feng: Pharmacology, Institute of Materia Medica, CAMS, Beijing, China
  • Abstract:

    Backgrounds

    Ischemic stroke is the most fatal reason for permanent disability all over the world. There are about 8 million ischemic stroke patients and more than 1.5 million incidences each year in China. It is a worldwide challenge to develop a new drug for treatment of ischemic stroke.

    Aims

    Several therapeutic agents were developed in last two

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses